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Cancer research has devoted most of its energy over the past decades on unraveling the control mechanisms
within tumor cells that govern its behavior. From this we know that the onset of cancer is the result of cumulative
genetic mutations and epigenetic alterations in tumor cells leading to an unregulated cell cycle, unlimited
replicative potential and the possibility for tissue invasion and metastasis. Until recently it was often thought that
tumors are more or less undetected or tolerated by the patient’s immune system causing the neoplastic cells to
divide and spread without resistance. However, it is without any doubt that the tumor environment contains a
wide variety of recruited host immune cells. These tumor infiltrating immune cells influence anti-tumor responses in
opposing ways and emerges as a critical regulator of tumor growth. Here we provide a summary of the relevant
immunological cell types and their complex and dynamic roles within an established tumor microenvironment. For
this, we focus on both the systemic compartment as well as the local presence within the tumor
microenvironment of late-stage non-small cell lung cancer (NSCLC), admitting that this multifaceted cellular
composition will be different from earlier stages of the disease, between NSCLC patients. Understanding the
paradoxical role that the immune system plays in cancer and increasing options for their modulation may alter the
odds in favor of a more effective anti-tumor immune response. We predict that the future standard of care of lung
cancer will involve patient-tailor-made combination therapies that associate (traditional) chemotherapeutic drugs
and biologicals with immune modulating agents and in this way complement the therapeutic armamentarium for
this disease.
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Current NSCLC treatment
Treatment of lung cancer is currently based on the
patient’s clinical signs and symptoms, tumor stage and
subtype, medical and family history, and data from im-
aging and laboratory evaluation. Most conventional can-
cer therapies, such as radiotherapy and chemotherapy
are restricted by adverse effects on normal tissue. Cur-
rently NSCLC therapy is moving towards personalized
medicine where the genetic profile of each patient’s
tumor is identified and specific therapies that inhibit the* Correspondence: j.hegmans@erasmusmc.nl
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reproduction in any medium, provided the orkey targets of the oncogenic activation are targeted. In
approximately 60% of all NSCLC cases, specific muta-
tions can be identified, of which ± 20% can be targeted
with specific drugs at this moment (e.g. erlotinib, gefiti-
nib, crizotinib). However, most patients receiving con-
ventional cancer treatments or targeted drugs will
experience a relapse of tumor growth at a certain time.
This sobering outcome demonstrates the necessity of
innovative approaches in NSCLC treatment.
Recently, experimental findings and clinical observa-
tions have led to cancer-related immune inflammation
being acknowledged as an additional hallmark of cancer
[1,2]. There is currently overwhelming evidence that
several immunological cell types of the host influence
cancer incidence, cancer growth, response to therapyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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immune system plays a paradoxical role by either pre-
venting cancer growth or in sculpting tumor escape and
stimulates its development. A better understanding of
the interaction between cancer cells and host immune
cells within the tumor environment is of importance for
further progress in cancer treatment. This is an ex-
tremely difficult task because of the complicated cancer-
host immune interactions. The field that studies these
interactions, termed cancer immunology, is rapidly pro-
gressing. It provides insights into the contribution of the
immune system in processes such as tumor invasiveness,Figure 1 The tumor microenvironment is a heterogeneous and comp
including endothelial cells and their precursors, pericytes, smooth-mu
the connective tissue or extra-cellular matrix (e.g. collagen). Leukocyte
components of these infiltrates include natural killer (T) cells, neutrophils, B
macrophages and dendritic cells [3-7]. Based on their functions, these cells
antitumor response (right) and cells with a detrimental effect (left). From m
these cells have within the micro-environment. The net effect of the intera
within the environment of an established tumor participates in determinin
survival and proliferation.metastasis, and angiogenesis and may predict the re-
sponse to treatment. Most importantly, it also provides
opportunities for improved anti-cancer therapies. Modu-
lation of the patient’s immune system combined with
anti-tumor treatments offers the prospect of tailoring
treatments much more precisely and better efficacy for
patients with advanced lung cancer.Immune cells involved in tumorogenesis
The individual immune related tumor infiltrating cell
types are discussed below (Figure 1).lex system of tumor cells (black) and ‘normal’ stromal cells,
scle cells, and fibroblasts of various phenotypes, located within
infiltration is an important characteristic of cancer and the main
- and T-lymphocyte subsets, myeloid derived suppressor cells,
can be divided into cells with a potentially positive impact on the
ast cells and T helper 17 cells it is yet ambiguous what kind of effect
ctions between these various cell types and their secreted products
g anti-tumor immunity, angiogenesis, metastasis, overall cancer cell
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Natural killer (NK) cells (expressing the surface markers
CD16 and CD56, but not CD3) are lymphocytes that
play an important role in the rejection of tumors with-
out previous sensitization and without restriction by the
major histocompatibility complex (MHC) [8,9]. NK cells
eradicate tumors through multiple killing pathways, in-
cluding direct tumor cell killing. They also secrete cyto-
kines and chemokines like Interleukin (IL) IL-10, Tumor
Necrosis Factor (TNF)-α, and the principal NK-derived
cytokine Interferon (IFN)-γ, which can coordinate the
innate and adaptive immune responses to tumor cells
and may lead to apoptosis of the attacked cells.
A large cohort study showed that an increase in NK
cells in tumor tissue is a strong independent prognostic
factor for the survival of lung cancer patients [10]. This
is confirmed in mouse models, showing that stimulation
of NK cell function protected against NSCLC metastasis
[11,12], while depletion enhanced lung cancer metastasis
[13]. However, it was recently shown that although the
frequencies of NK cells in blood do not differ from
healthy controls, stimulated blood NK cells from NSCLC
patients with advanced disease had a reduced granzyme
B and perforin A expression, lower production of IFN-γ,
and decreased cytotoxic function indicating that these
cells are functionally impaired in comparison with
healthy controls [14,15]. Adoptive transfer of allogeneic,
in vitro activated and expanded NK cells from haploi-
dentical donors was proven potentially clinically effective
in NSCLC [16].
Natural killer T (NKT) cells (CD16+, CD56+, CD3+)
are a subset of NK cells that have been found in the per-
ipheral blood, tumor tissue and pleural effusions of lung
cancer patients in decreased numbers and with reduced
functions [17,18]. It has been shown that NKT cells in
cancer patients produce a decreased amount of IFN-γ
and are therefore less effective than NKT cells in healthy
controls [19,20]. They are currently exploited for cancer
treatment by harnessing these cells with CD1d agonist
ligands [21,22], or by adoptive transfer of NKT cells acti-
vated in vitro [23].
Mast cells
Accumulation of mast cells is common in angiogenesis-
dependent conditions, like cancer, as mast cells are a
major provider of proangiogenic molecules vascular
endothelial growth factor (VEGF), IL-8, transforming
growth factor (TGF)-β [24]. The density of mast cells in
NSCLC tumors is correlated with microvessel density
[25] and mast cells / histamine has a direct growth pro-
moting effect on NSCLC cell lines in vitro [26]. How-
ever, the role of mast cells in the prognosis in NSCLC
remains controversial [25,27-29]. Tumor-infiltrating
mast cells can directly influence proliferation andinvasion of tumors, by histamine, IL-8 and VEGF while
the production of TNF-α and heparin can suppress
tumor growth [26,30]. It has been shown that in NSCLC
mast cell counts were noted to increase as tumor stage
increased while another study did not show this correl-
ation [24,29]. Mast cells also play a central role in the
control of innate and adaptive immunity by interacting
with B and T cells (in particular Treg) and dendritic
cells. The controversy of mast cells in cancer seems to
be related to the type, microenvironment and stage of
cancer and their role may depend on the tumor environ-
ment [29,31,32]. Therapeutic intervention by targeting
mast cells, although technically possible [33], is too early
without more knowledge on the paradoxical role of
these cells in individual cases.Neutrophils
Neutrophils play a major role in cancer biology. They
make up a significant portion of the infiltrating immune
cells in the tumor and the absolute neutrophils count
and the neutrophils to lymphocyte ratio in blood are
independent prognostic factors for survival of NSCLC
[34-36]. Neutrophils are attracted to the tumor under
the influence of specific chemokines, cytokines and cell
adhesion molecules. Tumor-associated neutrophils
(TAN) have polarized functions and can be divided into
the N1 and N2 phenotype in a context-dependent man-
ner [37,38]. The N1 phenotype inhibits tumor growth by
potentiating T cell responses while the N2 phenotype
promotes tumor growth [3]. The antitumor activities of
N1 neutrophils include expression of immune activating
cytokines (TNF-α, IL-12, GM-CSF, and VEGF), T cell
attracting chemokines (CCL3, CXCL9, CXCL10), lower
expression of arginase, and a better capacity of killing
tumor cells in vitro. N2 neutrophils support tumor
growth by producing angiogenic factors and matrix-
degrading enzymes, support the acquisition of a meta-
static phenotype, and suppress the anti-tumor immune
response by inducible nitric oxide synthase and arginase
expression. Neutrophils also influence adaptive immun-
ity by interacting with T cells [39], B-cells [40], and DC
[41]. In resectable NSCLC patients, intratumoral neutro-
phils were elevated in 50% of the patients and this was
associated with a high cumulative incidence of relapse
[42]. Recently, Fridlender et al. showed that TGF-β
acquired the polarized N2 tumor promoting phenotype
of neutrophils in a murine lung cancer model, and
blocking of TGF-β shifted towards N1 tumor rejecting
neutrophils with acquisition of anti-tumor activity
in vitro and in vivo [43]. Blockade of TGF-β in humans
might be a potential utility to prevent polarization to-
wards the protumorigenic N2 phenotype and thereby
may result in retarding tumor growth.
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B-cells may affect the prognosis of patients with lung can-
cer, as patients with stage I NSCLC contain more intratu-
moral germinal centers with B-lymphocytes than patients
with stages II to IV [44]. These tertiary (T-BALT) struc-
tures provide some evidence of an adaptive immune re-
sponse that could limit tumor progression in some
patients. For instance, the production of antibodies by B-
cells can activate tumor cell killing by NK cells and other
inflammatory cells [45]. Auto-antibodies against tumor
antigens are commonly found in patients with lung cancer
[46-48] and can inhibit micrometastasis [49]. Recently, it
has been shown in mice that antibodies produced by B
cells interact with and activate Fcγ receptors on macro-
phages and in this way orchestrate antitumor activity [50]
or tumor-associated macrophages (TAM)-mediated en-
hancement of carcinogenesis [51]. Thus, the role of B cells
seems depending on the context.
CD4+ and CD8+ lymphocytes
CD4+ cells and CD8+ cells represent the strong effectors
of the adaptive immune response against cancer [52].
There is controversy on the impact of T cells and their
localization on the prognosis of lung cancer [53-59]. This
may be caused by the presence of a special subset of T
cells, the regulatory T cells, and myeloid-derived suppres-
sor cells which are discussed below. Also tumor-derived
factors can exhaust T lymphocytes or induce their apop-
tosis [60]. Recently it has been shown that cytotoxic T
lymphocytes (CTL) within the tumor (the tumor-
infiltrating lymphocytes [TIL]) are of beneficial prognostic
influence in resected NSCLC patients in both adenocar-
cinoma [61] and squamous cell carcinoma [62]. Tumor-
specific CD8+ effector T-cells are normally present at a
low frequency in cancer patients, but can be expanded up
to 50% of the total circulating CD8+ T-cells by dendritic
cell vaccination or adoptive T-cell transfer therapy [63-
65]. To enhance existing anti-tumor responses, recombin-
ant CD40 ligand or CD40 activating antibodies are investi-
gated as substitute for CD4+ T cell help [66]. Blocking T
cell inhibitory molecules such as cytotoxic T lymphocyte
antigen-4 (CTLA-4), lymphocyte activation gene-3 (LAG-3),
T cell immunoglobulin mucin-3 (TIM-3), and pro-
grammed death-1 (PD-1) are currently investigated in
NSCLC to improve T cell homing and effector functions
[67,68]. Successes of these experimental therapies in small
subsets of patients demonstrate that CTL can be directed
against the tumor but mechanisms to induce CTL or
overcome the inactivation of T cell function seems neces-
sary to enable more patients from these treatments.
Regulatory T cells
Regulatory T cells (Treg), characterized by CD4+, CD25+,
Foxp3+, and CD127-, are T lymphocytes that aregenerated in the thymus (natural Treg) or induced in
the periphery (induced Treg) when triggered by sub-
optimal antigen stimulation and stimulation with TGF-
β and IL-10 [69]. Treg are further characterized by the
expression of glucocorticoid-induced TNF-receptor-
related-protein (GITR), lymphocyte activation gene-3
(LAG-3), and cytotoxic T-lymphocyte-associated antigen 4
(CTLA4).
In cancer patients, Treg confer growth and metastatic
advantages by inhibiting anti-tumor immunity. They
have this pro-tumoral effect by promoting tolerance via
direct suppressive functions on activated T-cells or via
the secretion of immunosuppressive cytokines such as
IL-10 and TGF-β [70,71]. Treg are present in tumor
tissue [72,73] and increased in peripheral blood of
NSCLC patients compared to healthy controls [74,75].
This increase in Treg was found to promote tumor
growth and was correlated with lymph node metastasis
[56,73,76,77] and poor prognosis [73,78]. Many factors
can increase Treg in NSCLC tumors, among them are
thymic stromal lymphopoietin (TSLP) [79] and intratu-
moral cyclooxygenase-2 (COX-2) expression [80]. Treg
are considered the most powerful inhibitors of antitu-
mor immunity [81]. As a result, there is substantial
interest for overcoming this barrier to enhance the
efficacy of cancer immunotherapy. Strategies include I).
Treg depletion by chemical or radiation lymphoablation
or using monoclonal antibodies or ligand-directed toxins
(daclizumab, basiliximab, denileukin diftitox [OntakTM],
RFT5-SMPT-dgA, and LMB-2) or with metronomic
cyclophosphamide. II). Suppression of their function
(ipilimumab, tremelimumad [anti-CTLA4], DTA-1 [anti-
GITR], denosumab [anti-RankL], modulation of Toll-like
receptor, OX40 stimulation or inhibiting ATP hydrolysis
using ectonucleotidase inhibitors). III). Inhibition of
tumoral homing by blocking the selective recruitment
and retention of Treg at tumor sites, e.g. CCL22, CXCR4,
CD103, and CCR2. IV). Exploitation of T-cell plasticity
by modulating IL-6, TGF-β, and PGE2 expression, e.g.
the COX-2 inhibitor celecoxib [82]. Till now, a strategy
that specifically target only Treg and no effector T cells
is lacking and procedures that depletes or modulates
all Treg should be avoided to minimize the risk of
autoimmune manifestations. However, studies modu-
lating Treg in patients are providing some early en-
couraging results supporting the concept that Treg
inhibitory strategies have clinical potential, particularly
in those therapies that simultaneously stimulate antitu-
mor immune effector cells.
Gamma delta T cells
Human γδ-T cells constitute 2-10% of T cells in blood
and exhibit natural cytolytic activity in an MHC-
unrestricted manner for microbial pathogens and tumor
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peptide antigens with a phosphate residue and isopente-
nylpyrophosphate (IPP) that accumulate in tumor cells
[83]. Because γδ-T cells recognize target cells in a unre-
stricted manner, they may exert antitumor effects even
on tumor cells with reduced or absent expression of
HLA and/or tumor antigens or by provision of an early
source of IFN-γ [83,84]. Phase I clinical trials of in vivo
activation of γδ-T cells with zoledronic acid plus IL-2 or
adoptive transfer of in vitro expanded γδ-T cells are
being conducted at present for lung cancer [85-87].
Th17 cells
Th17 cells are a subpopulation of CD4+ T helper cells
that are characterized by the production of interleukin-
17 (IL-17, also known as IL-17A). IL17 plays an import-
ant role in the host defenses against bacterial and fungal
infections by the activation, recruitment, and migration
of neutrophils [88,89]. In vitro experiments have shown
that IL-1β, IL-6, and IL23 promote Th17 generation and
differentiation from naïve CD4+ T cells [90]. Among the
other cytokines secreted by Th17 cells are IL-17F, IL-21,
IL-22, and TNF-α. The role of Th17 cells in cancer is
poorly understood. Th17 cells accumulate in malignant
pleural effusion from patients with lung cancer [90].
Also higher levels of IL-17A were detected in serum and
in tumor lesions of lung adenocarcinoma patients, indi-
cating a potential role of these cells in cancer [91]. It has
been shown that Th17 cells encouraged tumor growth
by inducing tumor vascularization or enhancing inflam-
mation, but other studies revealed also opposite roles for
Th17 cells. Recent data indicate that IL-17 may play
a role in the metastasis of lung cancer by promoting
lymphangiogenesis and is therefore an independent
prognostic factor in both overall and disease-free sur-
vival in NSCLC [92]. However, there is a distinct role for
Th17 and Th17-stimulated cytotoxic T-cells in the in-
duction of preventive and therapeutic antitumor immun-
ity in mice by the promoted recruitment of several
inflammatory leukocytes, like DC, CD4+ and CD8+ cells
[93]. So, it is controversial whether Th17 cells in cancer
are beneficial or antagonistic; this may be dependent on
the tumor immunogenicity, the stage of disease, and the
impact of inflammation and angiogenesis on tumor
pathogenesis [94].
Myeloid-derived suppressor cells
Myeloid-derived suppressor cells (MDSC) are a hetero-
geneous population of immature myeloid cells and mye-
loid progenitor cells. MDSC inhibit T cells activation
[95,96] in a nonspecific or antigen-specific manner, alter
the peptide presenting ability of MHC class I molecules
on tumor cells [97], influence B-cells [98], block NK cell
cytotoxicity [99-101], inhibit dendritic cell differentiation[102], and expand Treg [103,104] signifying their crucial
contribution in constituting a tumor suppressive envir-
onment. Furthermore, there is compelling evidence that
MDSC, by secreting MMP9 and TGF-β1, are also
involved in angiogenesis, vasculogenesis, and metastatic
spread [105].
MDSC suppress the immune system by the production
of reactive oxygen species (ROS), nitric oxide (NO),
peroxynitrite and secretion of the cytokines IL-10 and
TGF-β [106]. Upregulated arginase-I activity by MDSC
depletes the essential amino acid L-arginine, contribut-
ing to the induction of T cell tolerance by the down-
regulation of the CD3ζ chain expression of the
T cell receptor [107-110]. However, the mechanisms that
are used to suppress the immune responses are
highly dependent on the context of the microenviron-
ment [111].
An increased subpopulation of MDSC in the periph-
eral blood of NSCLC patients was detected that
decreased in those patients that responded to chemo-
therapy and patient undergoing surgery [112]. Because
MDSC play an important role in mediating immunosup-
pression, they represent a significant hurdle to successful
immune therapy in NSCLC. Therefore, targeting MDSC
in vivo with drugs like 5-fluorouracil (5FU), gemcitabine
or VEGF / c-kit blockers (e.g. sunitinib, imatinib, dasati-
nib) to elicit more potent anticancer effects is an
exciting development [113-115]. Treatment of mice with
all-trans retinoic acid (ATRA), along with NKT help,
convert the poorly immunogenic MDSC into fully effi-
cient APC and in this way reinforced anti-tumor im-
mune responses [116]. Other MDSC suppressing or
differentiation-inducing agents recently reported are 5-
aza-20-deoxycytidine, curcumin, IL-10, anti-IL4R apta-
mer, and vitamin D3 [117-120]. Agents that decrease
arginase activity, ROS and/or iNOS expression by
MDSC include Nor-NOHA, 1-NMMA, cyclooxygenase
2 inhibitors (celecoxib [121]), phosphodiesterase 5 inhi-
bitors (sildenafil, tadalafil [122]) or reactive oxygen spe-
cies inhibitors (nitroaspirin [123]). These agents promise
to be a fruitful avenue of investigation in the coming
years to overcome immune suppression associated by
MDSC in advanced tumors [113,114].
Tumor–associated macrophages
Macrophages are part of the innate immune system and
play important roles in the first line of defense against
foreign pathogens. They can be divided into M1 macro-
phages (classical activation) and M2 macrophages (alter-
native activation). M1 macrophages attract and activate
cells of the adaptive immune system and have anti-
tumor and tissue destructive activity, while the M2
phenotype has been linked to tumor-promoting activities
by subversion of adaptive immunity, promoting tumor
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eration, invasion and tumor dissemination. Macrophages
in tumors are usually referred to as tumor-associated
macrophages (TAM) and their presence can be substan-
tial (10–65% of the tumor stroma). In the beginning, the
TAM mainly consist of M1-like macrophages however,
when the tumor starts to invade and vascularize, there is
a skewing towards the M2 phenotype [124,125]. This
takes place especially at those regions in the tumor that
are hypoxic [126].
It has been reported by several groups that there is an
association between the number of tumor islet macro-
phages and NSCLC survival [58,127-132]. Moreover,
when looking at the different phenotypes of TAM (M1
and M2), it is shown that high numbers of M1 macro-
phages infiltrating the tumor are correlated with
improved survival [130,133]. On the other hand, the
presence of M2-like macrophages is associated with poor
clinical outcome [130,133].
Several strategies are currently investigated that influ-
ence M2 macrophages at multiple levels. For example,
blockade of factors and cytokines secreted by tumor or
immune cells to limit the induction of M2 macrophages
are investigated [134-136], however this results in loss of
typical M2 markers but not their function [137]. It has
been shown that inhibiting IκB kinase (IKK) reprograms
the M2 phenotype to the M1 subset [138,139]. Also
CD40 therapy seems to skew tumor-infiltrating macro-
phages towards the M1 phenotype [140]. Influencing the
attraction, the polarization or the activation of M2
macrophages may improve survival when combined with
standard or other immunotherapeutic regimens.
Dendritic cells
Dendritic cells (DC) are widely acknowledged as the
central surveillance cell type and play an important role
in the activation of lymphocyte subsets to control or
eliminate human tumors. Upon encountering tumor
cells or tumor-associated antigens, DC engulf this ma-
terial and begin migrating via lymphatic vessels to re-
gional lymphoid organs. The density immature DC
(Langerhans cell and interstitial DC) and mature DC,
present in the tumor microenvironment is highly pre-
dictive of disease-specific survival in early-stage NSCLC
patients [141] and the presence of DC in resected
NSCLC material is a good prognostic factor [10,142].
Interaction between the DC and tumor cells results in
the release of antitumour cytokines [143,144]. This sug-
gests that DC within the tumor microenvironment of
early-stage NSCLC are capable in initiating adaptive im-
mune responses in situ [145-147].
In the peripheral blood and regional lymph nodes of
lung cancer patients, the number and function of mature
DC is dramatically reduced [148,149], partly due toabnormal differentiation of myeloid cells (e.g. MDSC)
[150]. Tumor cells, stromal cells like fibroblasts, and
tumor-infiltrating immune cells and/or their secreted
products, like VEGF, M-CSF, IL-6, IL-10, and TGF-β are
also responsible for systemic and local DC defects [151-
154]. Affected DC are impaired in their ability to phago-
cytose antigen and to stimulate T cells, leading to a de-
fective induction of anti-tumor responses.
NSCLC-derived DC produce high amounts of the im-
munosuppressive cytokines IL-10 and TGF-β [155]. It
has been shown that the T cell co-inhibitory molecule
B7-H3 and programmed death receptor-ligand-1 (PD-
L1) are upregulated on tumor residing DC and these
molecules conveys mainly suppressive signals by inhibit-
ing cytokine production and T cell proliferation
[156,157].
Tumor-induced modulation is one of the main factors
responsible for tumor immune escape and correction of
DC function might be a requirement to develop more
effective immunotherapeutic strategies against cancer.
This might include targeting of those factors with neu-
tralizing antibodies (e.g. anti-VEGF, anti-IL-6) to revert
some of the inhibitory effects on DC. Another interest-
ing finding is that culturing monocytes from cancer
patients ex vivo, to circumvent the suppressive activity
of the tumor milieu, generates DC with a capacity to
stimulate allogeneic T cells [158,159]. [160] This finding
is important for active DC-based immunotherapeutic
approaches, where DC are generated ex vivo from
monocytes and after arming with tumor-associated anti-
gens, reinjected into the patient with the intension to re-
store proper presentation of tumor associated antigens
(TAA) and T cell activation [161-163]. This concept is
currently tested for NSCLC in therapeutic reality with
encouraging results on the immune response, safety and
tolerability, despite the small sample sizes of the trials
[161-163].
Immunogenic cell death biomarkers
Lung cancer is a complex disease with limited treatment
options, mainly caused by the close relationship between
neoplastic cells and healthy cells. To develop a more ef-
fective treatment for lung cancer, we have to focus on the
complex interactions that tumor cells have with the local
stromal compartment and the involved immune cells, and
all of their secreted factors. There is growing evidence that
the efficacy of many traditional therapeutic treatments
depends on their ability to induce proper immunogenic
tumor cell death. This specific release of signals upon
tumor cell death may lead to immune activation, and in
particular anti-tumor immunity, that contribute to the
therapeutic outcome for patients [164,165].
There are different candidate immune biomarkers that
can predict the efficacy of specific NSCLC anticancer
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already been proven useful for the early estimation of re-
sponse to chemotherapy [168-170]. Presence of mature
dendritic cells and CD4+ or CD8+ lymphocytes in
NSCLC tumors are independent prognostic factors for
overall survival, as described above [55,59,171,172]. In
addition, other potentially pivotal markers for lung can-
cer are p53-specific autoantibodies and pyridoxal kinase
(PDXK), the enzyme that generates the bioactive form of
vitamin B6 [173]. Also a group of immunogenic cell
death biomarkers called damage-associated molecular
pattern (DAMP) molecules, can serve as prognostic
markers for response to therapy and prognosis in cancer
patients [174]. DAMPs, such as surface-exposed calreti-
culin (ecto-CRT) and the high-mobility group box 1 pro-
tein (HMGB1); are released in the blood circulation by
late apoptotic and necrotic cells upon oxidative and
endoplasmic reticulum (ER) stress. In peripheral blood,
they bind to specific immune cells and trigger protective
T cell responses and promote phagocytosis. One of the
main functions of HMGB1 is the binding to specific
receptors on dendritic cells and other antigen presenting
cells, such as receptors for advanced glycation endpro-
ducts (RAGE) and toll-like receptors 4 (TLR4). It has
been described that the release of DAMP during cell
death is essential for the sustained therapy response after
chemotherapy and the efficiency of HMGB1 was found
to be increased when bacterial lipopolysaccharide (LPS),
DNA or nucleosomes were bound to it. Knockdown of
HMGB1 was observed to be associated with reduced
anticancer immune response and poor therapy outcome.
In contrary, overexpression of HMGB1 and its receptor
RAGE is pivotal for the metastasizing of the tumor cells
as it promotes neoangiogenesis [175]. Markers of im-
munogenic cell death are becoming a valuable tool in
clinical practice for diagnosis and prediction of response
to NSCLC therapy and prognosis [167].
Next to DAMP, there are other approaches using RNA-
and DNA-based immune modifiers to augment cancer
therapy efficacy by stimulating the immune system. Bac-
terial DNA is immunostimulatory and can be replaced
using synthetic oligodeoxynucleotides (ODN), for instance
CpG oligodeoxynucleotides. CpG ODN are synthetic
DNA sequences containing unmethylated cytosine-
guanine motifs with potent immune modulatory effects
via TLR 9 on DC and B cells [176]. They can induce cyto-
kines, activate NK cells, and elicit T cell responses that
lead to strong antitumor effects. It has been shown that
CpG ODN downregulates regulatory T cells and TGF-β in
peripheral blood of NSCLC patients [177].
Overall, analysis of new and conventional therapeutic
strategies should not only be focused on the direct cyto-
toxic effects of tumor cells but also on the initiation of
proper immune responses. Simultaneous modulation ofthe immune system by immune therapeutic approaches
can then induce synergistic anticancer efficacy [178].
Overall, the composition of the immunological cells and
cell death markers in the host is, next to the mutation
analysis and histological features of the tumor, likely to
determine the response to specific chemotherapeutic
agents and the prognosis of the patients.
Conclusion
In this review, we have shown that the immune system
plays a dual role in cancer development and progression
and determines the response to treatment in NSCLC.
These complex interactions between diverse immune
cell types and tumor cells that can actively favor tumor
rejection as well as tumor progression, depends on the
tumor type, stage and the types of immune cells that are
involved. The data presented here reinforce the import-
ance of full understanding of the intricacy of the cellular
interactions within the tumor microenvironment. There
is a rapid progress in the field of the cancer immunology
and the development of novel cancer immunotherapy
approaches. Therefore, tumor immunology will probably
be used more commonly in clinical practice in the fu-
ture, as increasing evidence indicates that the effective-
ness of several chemotherapies depends on the active
contribution of the different immune effectors. Selecting
conventional chemotherapeutic agents that induce
proper immunogenic tumor death can synergize with
immune response modifiers to revolutionize cancer
treatment [179]. Understanding the local and systemic
immune mechanisms will lead to new potential thera-
peutic targets.
We predict that the future standard of care of lung
cancer will involve patient tailored combination therap-
ies that associate molecules that target specific genetic
mutations or chemotherapeutic drugs with immune
modulating agents, driven by the increasing understand-
ing of the immune system in the cancer cell’s environ-
ment. The future for cancer treatment is bright if we are
able to: I). Find a chemotherapeutic drug that induces
immunogenic cell death in tumor cells while leaving the
normal cells and stimulating immune cells intact. II). Ex-
plore ways to efficiently activate the good-natured im-
mune system, for instance, the adoptive transfer of
in vitro expanded activated T-cells or NK-cells, and III).
Modulate the tumor environment to reduce local and
systemic immune suppressive components while limiting
potential side-effects for the patient; e.g. by the depletion
of Treg by denileukin diftitox or polarizing the M2
macrophage towards the M1 subtype. The treatment has
to be tuned to the cellular make-up of each patient indi-
vidually, based on their own both tumoral and immuno-
logical characteristics, rather than by the anatomic
location of the tumor in the body or by the tumor
Heuvers et al. BMC Cancer 2012, 12:580 Page 8 of 12
http://www.biomedcentral.com/1471-2407/12/580histology or genetic make-up. This individualized, multi-
targeted approach will be able to redress the balance
towards efficacious antitumor responses that can im-
prove the overall survival for more patients.
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